article thumbnail

STAT+: Pharmalittle: More than 9 in 10 pharmacy techs report drug shortages; Yale and VA strike deal over ketamine patent royalties

STAT

Krystal, who worked for both Yale and the VA at the time, and his co-inventors applied for patents with VA funding starting in 2006 for a ketamine nasal spray to treat depression and suicidal ideation. Yale and the VA agreed in 2003 to share royalties on patents with inventors from both institutions.

article thumbnail

2022 spells change for EU pharmaceutical legislation

European Pharmaceutical Review

The review was impacted by Brexit and the COVID-19 pandemic, which compounded existing issues surrounding high drug pricing and patient access that had been brewing since 2016 and highlighted several shortcomings in the EU’s pharmaceutical system. THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION; 2006.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Episode 864: Why Did ISMP Remove the Do Not Crush List from Their Website?

Pharmacy Joe

The removal appears to be in response to the publication of a 2021 article in the International Journal of Pharmaceutical Compounding. The list was originally compiled and updated by John Mitchell, PharmD, who passed away on June 10, 2014.

Dosage 111
article thumbnail

From Healing to Harm: The Unintended Consequences of Polypharmacy in Seniors

PharmD Live

The side effects can compound, resulting in a greater negative impact on a patient’s health than the individual effects of one medication alone. Institute of Medicine, 2006). Adverse Drug Reactions (ADRs) Adverse drug reactions are a major concern in polypharmacy. million people annually in the U.S. Preventing Medication Errors.

article thumbnail

Market outlook to 2032: future trends across the seven major markets

European Pharmaceutical Review

Insomnia market Dual orexin receptor antagonists (DORAs) [dual orexin receptor antagonists (DORAs)]… offer a new mechanism of action [in treating insomnia]” Across the seven major markets, the insomnia market is anticipated to grow at a compound annual growth rate (CAGR) of 2.6 percent from $3.2 billion in 2022 to $4.1

article thumbnail

A history of Pfizer

pharmaphorum

It was at this time they set their site at Sandwich in the UK, initially just to finish processing compounds imported from America, but due to tariffs on imported products the company rapidly expanded the plant to accommodate producing medicines from scratch. Likewise, tanezumab, an anti-osteoarthritic, failed in trials.

article thumbnail

Episode 864: Why Did ISMP Remove the Do Not Crush List from Their Website?

Pharmacy Joe

The removal appears to be in response to the publication of a 2021 article in the International Journal of Pharmaceutical Compounding. The list was originally compiled and updated by John Mitchell, PharmD, who passed away on June 10, 2014.

Dosage 52